BioCryst Pharmaceuticals
BCRX
BCRX
195 hedge funds and large institutions have $1.65B invested in BioCryst Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 61 increasing their positions, 61 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 61
0.2% less ownership
Funds ownership: 59.07% → 58.87% (-0.2%)
Holders
195
Holding in Top 10
3
Calls
$81.8M
Puts
$68.5M
Top Buyers
| 1 | +$31.8M | |
| 2 | +$28.3M | |
| 3 | +$15.3M | |
| 4 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$13.3M |
| 5 |
D.E. Shaw & Co
New York
|
+$12.8M |
Top Sellers
| 1 | -$53.4M | |
| 2 | -$25.9M | |
| 3 | -$21.5M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$16.7M |